CC-5013 in Treating Patients With Recurrent Glioma

You may be eligible if

• DISEASE CHARACTERISTICS:
• One of the following:
• * Histologically confirmed high-grade glioma
• * Glioblastoma multiforme
• * Gliosarcoma
• * Anaplastic astrocytoma
• * Anaplastic oligodendroglioma
• * Anaplastic mixed oligoastrocytoma
• * Malignant glioma/astrocytoma, not otherwise specified
• * Meningioma
• * Hemangioblastoma
• * Ependymoma
• * Primitive neuroectodermal tumors
• * Hemangiopericytoma
• * Progressive glioma
• * Clinically and radiographically diagnosed brain stem glioma
• Progressive or recurrent disease as determined by CT scan or MRI
• * Biopsy allowed for prior recent (i.e., within the past 12 weeks) resection of recurrent or progressive tumor
• Must have failed prior radiotherapy
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 60-100%
• Life expectancy:
• More than 8 weeks
• Hematopoietic:
• WBC at least 2,300/mm\^3
• Platelet count at least 90,000/mm\^3
• Hemoglobin at least 8 g/dL (transfusions allowed)
• Hepatic:
• Bilirubin less than 3 times upper limit of normal (ULN)
• SGOT less than 3 times ULN
• No significant active hepatic disease
• Renal:
• Creatinine less than 2.0 mg/dL OR
• Creatinine clearance at least 60 mL/min
• No significant active renal disease
• Cardiovascular:
• No significant active cardiac disease
• Other:
• No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
• No significant active psychiatric disease
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 2 months after study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 2 weeks since prior interferon
• No concurrent immunotherapy
• Chemotherapy:
• At least 6 weeks since prior nitrosoureas
• At least 4 weeks since prior temozolomide or carboplatin
• At least 3 weeks since prior procarbazine
• At least 2 weeks since prior vincristine
• At least 4 weeks since other prior cytotoxic chemotherapy
• No concurrent chemotherapy
• Endocrine therapy:
• At least 2 weeks since prior tamoxifen
• Concurrent steroids allowed for control of the signs and symptoms of increased intracranial pressure if on a stable dose for at least the past 5 days
• Radiotherapy:
• See Disease Characteristics
• At least 2 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery:
• See Disease Characteristics
• At least 2 weeks since prior tumor resection
• Other:
• At least 2 weeks since other prior noncytotoxic agents
• Concurrent enzyme-inducing antiepileptic drugs allowed
• No concurrent rifampin
• No concurrent grapefruit juice
• No other concurrent investigational agents